ARS Pharmaceuticals Inc (NASDAQ:SPRY) currently has a daily average trading volume of 1.26M but it saw 1135140 shares traded in last market. With a market cap of 1.32B USD, the company’s current market price of $13.55 came rising about 0.52 while comparing to the previous closing price of $13.48. In past 52 weeks, the stock remained buoying in the range of price level as high as $18.51 and as low as $6.04. In the recent trading on the day, stock has struck highest price mark of $13.15 while lowest mark touched by it was $13.68.
Taking a look at 20-day trading activity of ARS Pharmaceuticals Inc (SPRY) gives us an average price of $11.52, while its current price level is -26.80% below from 52-week high level whereas it is 124.34% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $12.88 while that of 200 days or SMA-200 reads an average of $11.66. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.85% during that period while stretching the period over a month that decreases to 7.12%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 67.45 which implies that the stock is in neutral territory.
Raymond James upgraded its recommendation for the stock as a “Strong Buy” from “Outperform” on August 13, 2024 while assigning a price target range of $18-$22. Leerink Partners issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $19 and $20.
Over the week, SPRY’s stock price is moving 19.28% up while it is 23.63% when we observe its performance for the past one month. Year-to-date it is 28.44% up and over the past year, the stock is showing an upside performance of 123.97%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of -0.11 while estimate for next year EPS is -0.55. In next quarter, company is expected to be making quarterly sales of $16.71M as analysts are expecting the sales for current fiscal year at $20.26M and seeing the company making $122.3M in sales next year. Moreover, analysts are in estimates of $17.68M for current-quarter revenue.
Currently, ARS Pharmaceuticals Inc’s total number of outstanding shares is 97.15M with 23.19% of that held by the insiders while 68.25% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -24.43% and return on equity (ROE) at -22.41%. Stock’s beta reads 1.00. Stock has a price to book (P/B) ratio of 6.55 while price to sale or P/S ratio amounts to 512.40. Its return on asset (ROA) is -21.07% on average.
